#BEGIN_DRUGCARD DB00895

# AHFS_Codes:
36:30.00

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Pre-pen

# CAS_Registry_Number:
2642-55-9

# ChEBI_ID:
59297

# Chemical_Formula:
C28H46N6O8S

# Chemical_IUPAC_Name:
Not Available

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Benzylpenicilloyl Polylysine is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. The quantitation of in vitro IgE antibodies to the benzylpenicilloyl determinant is a useful tool for evaluating allergic subjects.

# Dosage_Forms:
Liquid	Intradermal

# Drug_Category:
Not Available

# Drug_Interactions:
Carbinoxamine	Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine. Treatment with systemic histamine H1 antagonists such as carbinoxamine should be suspended for benzylpenicilloyl-polylysine skin testing to minimize the potential for false negative results. Delay skin testing until the systemic effects of the antihistamine have dissipated. A histamine skin test may be used to assess residual antihistaminic effects.

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
-0.8

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Benzylpenicilloyl Polylysine

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C22H32N4O6S.C6H14N2O2/c1-22(2)17(21(31)32)26-19(33-22)16(25-15(27)12-13-8-4-3-5-9-13)18(28)24-11-7-6-10-14(23)20(29)30;7-4-2-1-3-5(8)6(9)10/h3-5,8-9,14,16-17,19,26H,6-7,10-12,23H2,1-2H3,(H,24,28)(H,25,27)(H,29,30)(H,31,32);5H,1-4,7-8H2,(H,9,10)/t14-,16?,17+,19-;5-/m11/s1

# InChI_Key:
InChIKey=IMPVZRLKKKXMKQ-SGDOCVTFSA-N

# Indication:
For use as a adjunct in assessing the risk of administering penicillin (benzylpenicillin or penicillin G).

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
895

# Mechanism_Of_Action:
The skin test for penicillin demonstrates the presence or absence of specific IgE antibodies to major and minor penicillin determinants. IgE antibodies to major determinants can be detected by using benzylpenicilloyl polylysine. A penicillin skin test predicts only the presence of IgE antibodies for the major or minor penicillin determinants at the time of application and does not predict the future development of IgE-mediated reactions during subsequent courses of penicillin. Benzylpenicilloyl polylysine reacts specifically with penicilloyl skin sensitizing antibodies (reagins) to produce immediate wheal and flare reactions which may reflect increased risk of allergic reactions to subsequent penicillin therapy.

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
626.765

# Molecular_Weight_Mono:
626.309783168

# Organisms_Affected:
Humans and other mammals

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164754810

# Pharmacology:
Benylpenicilloyl polylysine is penicilloyl bound to polylysine and is considered to be the major determinant of penicillin metabolism; it is used as a skin-testing reagent to detect immunoglobulin E antibodies in people with a history of penicillin allergy. If skin testing using benzylpenicilloyl and penicillin G (as the sole source of minor determinants) is negative, approximately 97% of patients with a negative skin test will tolerate penicillin.

# Predicted_LogP_Hydrophobicity:
0

# Predicted_LogS:
0

# Predicted_Water_Solubility:
Not Available

# Primary_Accession_No:
DB00895

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
Not Available

# PubChem_Substance_ID:
Not Available

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
APRD00822

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
Not Available

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Symptoms of overdose include urticaria, generalized pruritus, local swelling, generalized flushing, anaphylaxis, bronchospasm, fainting and maculopapular eruption.

# Update_Date:
2012-04-19 13:15:45 -0600

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7436456	Chandra RK, Joglekar SA, Tomas E: Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
FCER1G

# Drug_Target_1_GenBank_ID_Gene:
M33195

# Drug_Target_1_GenBank_ID_Protein:
182488

# Drug_Target_1_GeneCard_ID:
FCER1G

# Drug_Target_1_Gene_Name:
FCER1G

# Drug_Target_1_Gene_Sequence:
>261 bp
ATGATTCCAGCAGTGGTCTTGCTCTTACTCCTTTTGGTTGAACAAGCAGCGGCCCTGGGA
GAGCCTCAGCTCTGCTATATCCTGGATGCCATCCTGTTTCTGTATGGAATTGTCCTCACC
CTCCTCTACTGTCGACTGAAGATCCAAGTGCGAAAGGCAGCTATAACCAGCTATGAGAAA
TCAGATGGTGTTTACACGGGCCTGAGCACCAGGAACCAGGAGACTTACGAGACTCTGAAG
CATGAGAAACCACCACAGTAG

# Drug_Target_1_General_Function:
Involved in immune function

# Drug_Target_1_General_References:
2138619	Kuster H, Thompson H, Kinet JP: Characterization and expression of the gene for the human Fc receptor gamma subunit. Definition of a new gene family. J Biol Chem. 1990 Apr 15;265(11):6448-52.

# Drug_Target_1_HGNC_ID:
HGNC:3611

# Drug_Target_1_HPRD_ID:
00916

# Drug_Target_1_ID:
55

# Drug_Target_1_Locus:
1q23

# Drug_Target_1_Molecular_Weight:
9668

# Drug_Target_1_Name:
High affinity immunoglobulin epsilon receptor gamma-subunit

# Drug_Target_1_Number_of_Residues:
86

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF02189	ITAM

# Drug_Target_1_Protein_Sequence:
>High affinity immunoglobulin epsilon receptor gamma-subunit precursor
MIPAVVLLLLLLVEQAAALGEPQLCYILDAILFLYGIVLTLLYCRLKIQVRKAAITSYEK
SDGVYTGLSTRNQETYETLKHEKPPQ

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
1-18

# Drug_Target_1_Specific_Function:
The gamma subunit has a critical role in allowing the IgE Fc receptor to reach the cell surface

# Drug_Target_1_SwissProt_ID:
P30273

# Drug_Target_1_SwissProt_Name:
FCERG_HUMAN

# Drug_Target_1_Synonyms:
Fc-epsilon RI-gamma
FceRI gamma
High affinity immunoglobulin epsilon receptor gamma-subunit precursor
IgE Fc receptor gamma-subunit

# Drug_Target_1_Theoretical_pI:
7.24

# Drug_Target_1_Transmembrane_Regions:
24-44

# Drug_Target_2_Cellular_Location:
Membrane
single-pass type I membrane protein

# Drug_Target_2_Chromosome_Location:
Not Available

# Drug_Target_2_Drug_References:
11752352	Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.
17016423	Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.
17139284	Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
7436456	Chandra RK, Joglekar SA, Tomas E: Penicillin allergy: anti-penicillin IgE antibodies and immediate hypersensitivity skin reactions employing major and minor determinants of penicillin. Arch Dis Child. 1980 Nov;55(11):857-60.

# Drug_Target_2_Essentiality:
Non-Essential

# Drug_Target_2_GenAtlas_ID:
FCER1A

# Drug_Target_2_GenBank_ID_Gene:
X06948

# Drug_Target_2_GenBank_ID_Protein:
31318

# Drug_Target_2_GeneCard_ID:
FCER1A

# Drug_Target_2_Gene_Name:
FCER1A

# Drug_Target_2_Gene_Sequence:
>774 bp
ATGGCTCCTGCCATGGAATCCCCTACTCTACTGTGTGTAGCCTTACTGTTCTTCGCTCCA
GATGGCGTGTTAGCAGTCCCTCAGAAACCTAAGGTCTCCTTGAACCCTCCATGGAATAGA
ATATTTAAAGGAGAGAATGTGACTCTTACATGTAATGGGAACAATTTCTTTGAAGTCAGT
TCCACCAAATGGTTCCACAATGGCAGCCTTTCAGAAGAGACAAATTCAAGTTTGAATATT
GTGAATGCCAAATTTGAAGACAGTGGAGAATACAAATGTCAGCACCAACAAGTTAATGAG
AGTGAACCTGTGTACCTGGAAGTCTTCAGTGACTGGCTGCTCCTTCAGGCCTCTGCTGAG
GTGGTGATGGAGGGCCAGCCCCTCTTCCTCAGGTGCCATGGTTGGAGGAACTGGGATGTG
TACAAGGTGATCTATTATAAGGATGGTGAAGCTCTCAAGTACTGGTATGAGAACCACAAC
ATCTCCATTACAAATGCCACAGTTGAAGACAGTGGAACCTACTACTGTACGGGCAAAGTG
TGGCAGCTGGACTATGAGTCTGAGCCCCTCAACATTACTGTAATAAAAGCTCCGCGTGAG
AAGTACTGGCTACAATTTTTTATCCCATTGTTGGTGGTGATTCTGTTTGCTGTGGACACA
GGATTATTTATCTCAACTCAGCAGCAGGTCACATTTCTCTTGAAGATTAAGAGAACCAGG
AAAGGCTTCAGACTTCTGAACCCACATCCTAAGCCAAACCCCAAAAACAACTGA

# Drug_Target_2_General_Function:
Not Available

# Drug_Target_2_General_References:
1472946	Padlan EA, Helm BA: A modeling study of the alpha-subunit of human high-affinity receptor for immunoglobulin-E. Receptor. 1992 Summer;2(2):129-44.
2964640	Shimizu A, Tepler I, Benfey PN, Berenstein EH, Siraganian RP, Leder P: Human and rat mast cell high-affinity immunoglobulin E receptors: characterization of putative alpha-chain gene products. Proc Natl Acad Sci U S A. 1988 Mar;85(6):1907-11.
2967464	Kochan J, Pettine LF, Hakimi J, Kishi K, Kinet JP: Isolation of the gene coding for the alpha subunit of the human high affinity IgE receptor. Nucleic Acids Res. 1988 Apr 25;16(8):3584.
8125119	Yagi S, Yanagida M, Tanida I, Hasegawa A, Okumura K, Ra C: High-level expression of the truncated alpha chain of human high-affinity receptor for IgE as a soluble form by baculovirus-infected insect cells. Biochemical characterization of the recombinant product. Eur J Biochem. 1994 Mar 1;220(2):593-8.

# Drug_Target_2_HGNC_ID:
HGNC:3609

# Drug_Target_2_HPRD_ID:
00917

# Drug_Target_2_ID:
18

# Drug_Target_2_Locus:
1q23

# Drug_Target_2_Molecular_Weight:
29596

# Drug_Target_2_Name:
High affinity immunoglobulin epsilon receptor subunit alpha

# Drug_Target_2_Number_of_Residues:
257

# Drug_Target_2_PDB_ID:
1RPQ

# Drug_Target_2_Pathway:
Not Available

# Drug_Target_2_Pfam_Domain_Function:
PF00047	ig

# Drug_Target_2_Protein_Sequence:
>High affinity immunoglobulin epsilon receptor alpha-subunit precursor
MAPAMESPTLLCVALLFFAPDGVLAVPQKPKVSLNPPWNRIFKGENVTLTCNGNNFFEVS
STKWFHNGSLSEETNSSLNIVNAKFEDSGEYKCQHQQVNESEPVYLEVFSDWLLLQASAE
VVMEGQPLFLRCHGWRNWDVYKVIYYKDGEALKYWYENHNISITNATVEDSGTYYCTGKV
WQLDYESEPLNITVIKAPREKYWLQFFIPLLVVILFAVDTGLFISTQQQVTFLLKIKRTR
KGFRLLNPHPKPNPKNN

# Drug_Target_2_Reaction:
Not Available

# Drug_Target_2_Signals:
1-25

# Drug_Target_2_Specific_Function:
Binds to the Fc region of immunoglobulins epsilon. High affinity receptor. Responsible for initiating the allergic response. Binding of allergen to receptor-bound IgE leads to cell activation and the release of mediators (such as histamine) responsible for the manifestations of allergy. The same receptor also induces the secretion of important lymphokines

# Drug_Target_2_SwissProt_ID:
P12319

# Drug_Target_2_SwissProt_Name:
FCERA_HUMAN

# Drug_Target_2_Synonyms:
Fc-epsilon RI-alpha
FcERI
High affinity immunoglobulin epsilon receptor subunit alpha precursor
IgE Fc receptor, alpha-subunit

# Drug_Target_2_Theoretical_pI:
6.67

# Drug_Target_2_Transmembrane_Regions:
206-224

#END_DRUGCARD DB00895
